Plain-English translation of NCT07090317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether two immunotherapy medications called , given together with cetuximab (a medication you may already know), can help people whose advanced head and neck cancer has stopped responding to standard treatments. The study will enroll 30 people and track how well this medication combination works and what side effects occur.
People with advanced head and neck cancer that has progressed after two or more rounds of chemotherapy or other standard treatments have very limited options. This trial exists to see whether this new combination of immunotherapy drugs can offer hope for patients who have run out of conventional treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive the medication combination through an IV infusion every 21 days (about once every three weeks). You will continue receiving this treatment until your disease stops responding, side effects become too severe, or other stopping criteria are met. Throughout the trial, you will have regular blood tests, scans, and doctor visits to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Enrollment target
~30 participants
Started
July 2025
Primary completion
August 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guoxin Ren, M.D.
the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.